Loading clinical trials...
Loading clinical trials...
Upadacitinib Versus Infliximab as Second-Line Treatment for Acute Severe Ulcerative Colitis: Multicenter, Open-Label, Randomized Controlled Trial
Conditions
Interventions
upadacitinib
Infliximab
Locations
4
China
Ankang Central Hospital
Ankang, Shaanxi, China
3201 Hospital
Hanzhong, Shaanxi, China
Xijing Hosipital of Digestive Disease
Xi'an, Shaanxi, China
Shaanxi Provincial Nuclear Industry 215 Hospital
Xianyang, Shaanxi, China
Start Date
April 20, 2026
Primary Completion Date
April 1, 2028
Completion Date
November 1, 2028
Last Updated
April 24, 2026
Lead Sponsor
Xijing Hospital of Digestive Diseases
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions